Andere Sprachen Natera, Inc.

Aktien

A14VPJ

US6323071042

NTRA

Gesundheitspflege Einrichtungen

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 11.05.2026			Vorbörslich 13:54:46
199,14 ^USD	+2,52 %		199,44	+0,15 %

07.05.	Natera, Inc., Q1 2026 Earnings Call, May 07, 2026
07.05.	Natera: Nettoverlust weitet sich im ersten Quartal aus, Umsatz steigt; Aktie gibt nachbörslich nach	MT

Andere Sprachen

07.05.	Natera: Q1 Earnings Snapshot
07.05.	Natera Q1 Net Loss Widens, Revenue Rises; Shares Drop After Hours
07.05.	(NTRA) Natera Expects Full Year 2026 Revenue Range $2.74B - $2.82B, vs. FactSet Est of $2.67B
07.05.	Earnings Flash (NTRA) Natera Posts Q1 Loss $0.60, vs. FactSet Est of $0.54 Loss
07.05.	Natera : Q1 2026 Earnings Presentation
07.05.	Earnings Flash (NTRA) Natera, Inc. Reports Q1 Revenue $696.6M, vs. FactSet Est of $617.1M
07.05.	Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07.05.	Natera Reports First Quarter 2026 Financial Results
06.05.	Natera Insider Sold Shares Worth $693,560, According to a Recent SEC Filing
04.05.	Weekly Earnings Calendar: Palantir, AMD, AXA and Engie in the Spotlight
04.05.	Weekly Earnings Calendar: Palantir, AMD, AXA and Engie in the Spotlight
30.04.	Natera to Report its First Quarter Results on May 7, 2026
30.04.	Natera Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing
30.04.	Natera Insider Sold Shares Worth $1,001,645, According to a Recent SEC Filing
22.04.	Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
22.04.	Natera, Inc. Features Prospera Evidence In Heart And Lung Transplantation Across 17 Presentations at ISHLT
13.04.	Natera, Inc. Highlights Allogene Therapeutic's Positive Interim Futility Analysis From Allogene Therapeutics MRD-Guided Alpha3 Trial In Large B-Cell Lymphoma
13.04.	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
09.04.	Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales
09.04.	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
07.04.	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
01.04.	Natera, Inc. Appoints Eric Rubin to the Board and Member of Nominating, Corporate Governance and Compliance Committee, Effective March 26, 2026
31.03.	Natera Inc Announces Signatera MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
31.03.	Natera Says Study Suggests Signatera May Help Older Breast Cancer Patients Avoid Surgery
31.03.	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery